PURPOSE: Successful use of @entity898 to control @entity146 and @entity146 in a hospitalized adolescent @entity1 with @entity72 ( @entity72 ) is described. SUMMARY: A 17-year-old Hispanic male with @entity72 and @entity717 was hospitalized for inpatient @entity146 treatment due to impulsive and violent behavior. Despite receiving various medications in the initial weeks of hospitalization, including intramuscular @entity2934 and @entity3933 injections (four days a week on average), the @entity1 continued to exhibit aggressive and unpredictable behaviors. Treatment with 20% @entity898 oral solution was initiated at a dosage of 600 mg twice daily as an adjunct to @entity1089 therapy. Over the next six weeks, reductions in the @entity1 's @entity146 , tantrums, and @entity146 were noted. The use of as-needed medications to control aggression was decreased, and the dosage of @entity1089 was lowered from 700 to 400 mg daily over the course of the hospitalization. @entity898 was well tolerated, with no observed or reported adverse effects. Unlike @entity1338 or @entity1774 (other medications used for @entity72 -related behavioral symptoms), @entity898 is not sedating; moreover, it lacks the metabolic, extrapyramidal, and endocrine adverse effects of atypical antipsychotics. Published data from small controlled trials and case reports suggest that @entity898 use is associated with improvements in @entity146 and aggression in prepubertal @entity1 with @entity72 ; these therapeutic benefits may be associated with @entity898 's glutamatergic, dopaminergic, antioxidant, and anti-inflammatory properties. CONCLUSION: Treatment with @entity898 improved @entity72 symptoms, including @entity146 and aggression, in a teenage @entity1 .

@entity898 for treatment of XXXX symptoms.

@entity1 :: ('9606', 'Species') :: ['children', 'patient'] @entity3933 :: ('MESH:D004155', 'Chemical') :: ['diphenhydramine'] @entity146 :: ('MESH:D001523', 'Disease') :: ['psychiatric', 'aggressive behaviors', 'aggressive behavior', 'irritability'] @entity898 :: ('MESH:D000111', 'Chemical') :: ['Acetylcysteine', 'acetylcysteine'] @entity72 :: ('MESH:D002659', 'Disease') :: ['ASD', 'autism spectrum disorder'] @entity1338 :: ('MESH:D003000', 'Chemical') :: ['clonidine'] @entity717 :: ('MESH:D009069', 'Disease') :: ['intellectual disability'] @entity1774 :: ('MESH:D016316', 'Chemical') :: ['guanfacine'] @entity2934 :: ('MESH:D008140', 'Chemical') :: ['lorazepam'] @entity1089 :: ('MESH:C069541', 'Chemical') :: ['quetiapine']
@entity72 :: (MESH:D002659,Disease) :: ['autism spectrum disorder']
